GRTS vs. ATRA, BLUE, CLLS, SOPH, CCCC, MGTX, STRO, SLDB, TNYA, and PSTX
Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Cellectis (CLLS), SOPHiA GENETICS (SOPH), C4 Therapeutics (CCCC), MeiraGTx (MGTX), Sutro Biopharma (STRO), Solid Biosciences (SLDB), Tenaya Therapeutics (TNYA), and Poseida Therapeutics (PSTX). These companies are all part of the "biological products, except diagnostic" industry.
Atara Biotherapeutics (NASDAQ:ATRA) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 1 articles in the media. Gritstone bio's average media sentiment score of 0.00 equaled Atara Biotherapeutics'average media sentiment score.
Gritstone bio has lower revenue, but higher earnings than Atara Biotherapeutics. Gritstone bio is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Atara Biotherapeutics currently has a consensus price target of $28.00, indicating a potential upside of 4,820.05%. Gritstone bio has a consensus price target of $4.75, indicating a potential upside of 514.17%. Given Gritstone bio's higher possible upside, research analysts clearly believe Atara Biotherapeutics is more favorable than Gritstone bio.
Atara Biotherapeutics has a net margin of -671.70% compared to Atara Biotherapeutics' net margin of -926.13%. Atara Biotherapeutics' return on equity of -232.42% beat Gritstone bio's return on equity.
70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 48.5% of Gritstone bio shares are held by institutional investors. 3.7% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 4.6% of Gritstone bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Atara Biotherapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
Atara Biotherapeutics received 288 more outperform votes than Gritstone bio when rated by MarketBeat users. However, 69.46% of users gave Gritstone bio an outperform vote while only 67.56% of users gave Atara Biotherapeutics an outperform vote.
Summary
Gritstone bio beats Atara Biotherapeutics on 10 of the 16 factors compared between the two stocks.
Get Gritstone bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gritstone bio Competitors List
Related Companies and Tools
